Magnesium Therapy in Children With Cerebral Palsy
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02510222 |
Recruitment Status :
Completed
First Posted : July 29, 2015
Last Update Posted : February 10, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This study is considered a pilot exploratory study. Intervention, prospective, double-armed, randomized, placebo-control clinical trial.
The therapeutic effect of oral Magnesium sulfate on spasticity and constipation will be studied.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cerebral Palsy | Dietary Supplement: Oral magnesium sulfate Other: Placebo | Not Applicable |
Spasticity and constipation are major problems hindering improvement in motor development in children with cerebral palsy.
Decreasing spasticity will have a positive effect on motor development and quality of life for the child and his family.
The aim is to study the therapeutic and adverse effects of oral magnesium sulfate therapy on spasticity and constipation in infants and children with cerebral palsy.
Hundred children with spastic cerebral palsy will be randomized to either intervention group n=50 will be treated with magnesium sulfate 4% orally for 28 days to treat spasticity and constipation in addition to their conventional treatment, or placebo group n=50 will receive conventional treatment and placebo.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 64 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Effect of Magnesium Therapy on Spasticity and Constipation in Children With Cerebral Palsy |
Study Start Date : | May 2015 |
Actual Primary Completion Date : | January 2016 |
Actual Study Completion Date : | January 2016 |

Arm | Intervention/treatment |
---|---|
Experimental: Oral Magnesium sulfate
Magnesium sulphate 4% concentration orally ( 65 mg per day for children one to three years of age; 110 mg per day for children four to eight years of age; 350 mg per day for children older than eight years) for 1 month
|
Dietary Supplement: Oral magnesium sulfate
Magnesium sulfate 4% concentration in a dose of 65 mg/day for infants and children aged 1-3 years , 110 mg/day for those 3-8 years and 350 mg/day for those above 9 years .Each 1 ml of the magnesium sulfate used contains 0.325 mEq (milliequivalent) of elemental magnesium which equals to 4 mg elemental magnesium . |
Placebo Comparator: Control
Fifty children with cerebral palsy will be treated with conventional therapy as physiotherapy. They will receive placebo.
|
Other: Placebo |
- Decrease in muscle tone evaluated by Modified Ashworth Index and constipation ROM-lll criteria [ Time Frame: 1 month ]
- Improvement in H/M ratio in H-reflex by electrophysiologic assessment [ Time Frame: 1 month ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 6 Months to 12 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age below12 years.
- Presence of spasticity without joint contracture Spasticity is defined as velocity dependent, increased resistance to passive muscle stretch.
- Acceptance of caregivers to participate in the study and signing the written consent.
- Constipation will be defined according to Rome lll criteria.presence of at least 2 of the following 2 motions week, history of painful or hard bowel movement, presence of large diameter stools that stools that may obstruct the toilets (Burgers et al., 2012).
Exclusion Criteria:
- Severe growth retardation (Below the 10th centile for weight and length charts children with cerebral palsy).
- Gastrostomy tube feeding.
- Joint contractures.
- Congenital malformations.
- Suspected inborn error of metabolism.
- Suspected inherited neurologic disease.
- Care giver's refusal to participate in the study.
- Occurrence of side effects of oral magnesium sulfate.
- Patients with cardiac, renal, GIT problem or chronic diarrhea.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02510222
Egypt | |
Children's Hospital, Faculty of Medicine, Ain Shams University | |
Cairo, Egypt, 11381 |
Principal Investigator: | Sahar MA Hassanein, PhD, MD | Pediatric department, Faculty of Medicine , Ain Shams University |
Responsible Party: | Sahar M.A. Hassanein, MD, Professor of Pediatrics , Faculty of Medicine, Ain Shams University |
ClinicalTrials.gov Identifier: | NCT02510222 |
Other Study ID Numbers: |
Pediatrics MS |
First Posted: | July 29, 2015 Key Record Dates |
Last Update Posted: | February 10, 2017 |
Last Verified: | February 2017 |
child |
Cerebral Palsy Nervous System Diseases Brain Damage, Chronic Brain Diseases Central Nervous System Diseases Magnesium Sulfate Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs |
Anesthetics Central Nervous System Depressants Anti-Arrhythmia Agents Anticonvulsants Calcium Channel Blockers Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Calcium-Regulating Hormones and Agents Tocolytic Agents Reproductive Control Agents |